Potential of pre-diagnostic metabolomics for colorectal cancer risk assessment or early detection

IF 6.8 1区医学 Q1 ONCOLOGY

NPJ Precision Oncology Pub Date : 2024-10-27 DOI:10.1038/s41698-024-00732-5

Teresa Seum, Clara Frick, Rafael Cardoso, Megha Bhardwaj, Michael Hoffmeister, Hermann Brenner

{"title":"Potential of pre-diagnostic metabolomics for colorectal cancer risk assessment or early detection","authors":"Teresa Seum, Clara Frick, Rafael Cardoso, Megha Bhardwaj, Michael Hoffmeister, Hermann Brenner","doi":"10.1038/s41698-024-00732-5","DOIUrl":null,"url":null,"abstract":"This systematic review investigates the efficacy of metabolite biomarkers for risk assessment or early detection of colorectal cancer (CRC) and its precursors, focusing on pre-diagnostic biospecimens. Searches in PubMed, Web of Science, and SCOPUS through December 2023 identified relevant prospective studies. Relevant data were extracted, and the risk of bias was assessed with the QUADAS-2 tool. Among the 26 studies included, significant heterogeneity existed for case numbers, metabolite identification, and validation approaches. Thirteen studies evaluated individual metabolites, mainly lipids, while eleven studies derived metabolite panels, and two studies did both. Nine panels were internally validated, resulting in an area under the curve (AUC) ranging from 0.69 to 0.95 for CRC precursors and 0.72 to 1.0 for CRC. External validation was limited to one panel (AUC = 0.72). Metabolite panels and lipid-based biomarkers show promise for CRC risk assessment and early detection but require standardization and extensive validation for clinical use.","PeriodicalId":19433,"journal":{"name":"NPJ Precision Oncology","volume":" ","pages":"1-13"},"PeriodicalIF":6.8000,"publicationDate":"2024-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514036/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Precision Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41698-024-00732-5","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

This systematic review investigates the efficacy of metabolite biomarkers for risk assessment or early detection of colorectal cancer (CRC) and its precursors, focusing on pre-diagnostic biospecimens. Searches in PubMed, Web of Science, and SCOPUS through December 2023 identified relevant prospective studies. Relevant data were extracted, and the risk of bias was assessed with the QUADAS-2 tool. Among the 26 studies included, significant heterogeneity existed for case numbers, metabolite identification, and validation approaches. Thirteen studies evaluated individual metabolites, mainly lipids, while eleven studies derived metabolite panels, and two studies did both. Nine panels were internally validated, resulting in an area under the curve (AUC) ranging from 0.69 to 0.95 for CRC precursors and 0.72 to 1.0 for CRC. External validation was limited to one panel (AUC = 0.72). Metabolite panels and lipid-based biomarkers show promise for CRC risk assessment and early detection but require standardization and extensive validation for clinical use.

Abstract Image

查看原文本刊更多论文

诊断前代谢组学在结直肠癌风险评估或早期检测方面的潜力。

本系统综述研究了代谢物生物标记物在结肠直肠癌（CRC）及其前体的风险评估或早期检测方面的功效，重点关注诊断前生物样本。截至 2023 年 12 月，在 PubMed、Web of Science 和 SCOPUS 中进行的搜索确定了相关的前瞻性研究。提取了相关数据，并使用 QUADAS-2 工具评估了偏倚风险。在纳入的 26 项研究中，病例数、代谢物鉴定和验证方法存在明显的异质性。有 13 项研究评估了单个代谢物，主要是脂类，有 11 项研究得出了代谢物组，有两项研究两者兼而有之。有九项研究对代谢物组进行了内部验证，结果显示 CRC 前体的曲线下面积 (AUC) 在 0.69 到 0.95 之间，CRC 的曲线下面积 (AUC) 在 0.72 到 1.0 之间。外部验证仅限于一个面板（AUC = 0.72）。代谢物面板和基于脂质的生物标记物有望用于 CRC 风险评估和早期检测，但临床应用还需要标准化和广泛的验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

NPJ Precision Oncology ONCOLOGY-

CiteScore

9.90

自引率

1.30%

发文量

审稿时长

18 weeks

期刊介绍： Online-only and open access, npj Precision Oncology is an international, peer-reviewed journal dedicated to showcasing cutting-edge scientific research in all facets of precision oncology, spanning from fundamental science to translational applications and clinical medicine.